JP2013512280A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512280A5
JP2013512280A5 JP2012542161A JP2012542161A JP2013512280A5 JP 2013512280 A5 JP2013512280 A5 JP 2013512280A5 JP 2012542161 A JP2012542161 A JP 2012542161A JP 2012542161 A JP2012542161 A JP 2012542161A JP 2013512280 A5 JP2013512280 A5 JP 2013512280A5
Authority
JP
Japan
Prior art keywords
optionally substituted
substituted
compound
alkylene
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512280A (ja
JP5607174B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/058572 external-priority patent/WO2011068881A1/en
Publication of JP2013512280A publication Critical patent/JP2013512280A/ja
Publication of JP2013512280A5 publication Critical patent/JP2013512280A5/ja
Application granted granted Critical
Publication of JP5607174B2 publication Critical patent/JP5607174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542161A 2009-12-01 2010-12-01 新規な三環式化合物 Active JP5607174B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26556309P 2009-12-01 2009-12-01
US61/265,563 2009-12-01
US36411610P 2010-07-14 2010-07-14
US61/364,116 2010-07-14
PCT/US2010/058572 WO2011068881A1 (en) 2009-12-01 2010-12-01 Novel tricyclic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014171336A Division JP5985557B2 (ja) 2009-12-01 2014-08-26 新規な三環式化合物

Publications (3)

Publication Number Publication Date
JP2013512280A JP2013512280A (ja) 2013-04-11
JP2013512280A5 true JP2013512280A5 (https=) 2014-01-23
JP5607174B2 JP5607174B2 (ja) 2014-10-15

Family

ID=44070404

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012542161A Active JP5607174B2 (ja) 2009-12-01 2010-12-01 新規な三環式化合物
JP2014171336A Expired - Fee Related JP5985557B2 (ja) 2009-12-01 2014-08-26 新規な三環式化合物
JP2016151711A Expired - Fee Related JP6298114B2 (ja) 2009-12-01 2016-08-02 新規な三環式化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014171336A Expired - Fee Related JP5985557B2 (ja) 2009-12-01 2014-08-26 新規な三環式化合物
JP2016151711A Expired - Fee Related JP6298114B2 (ja) 2009-12-01 2016-08-02 新規な三環式化合物

Country Status (41)

Country Link
US (5) US8426411B2 (https=)
EP (3) EP3266786A1 (https=)
JP (3) JP5607174B2 (https=)
KR (3) KR20170118230A (https=)
CN (4) CN108774237A (https=)
AR (1) AR079234A1 (https=)
AU (4) AU2010326108C1 (https=)
BR (1) BR112012013349B1 (https=)
CA (2) CA2781891C (https=)
CL (1) CL2012001397A1 (https=)
CO (1) CO6561771A2 (https=)
CR (2) CR20170159A (https=)
CY (2) CY1119175T1 (https=)
DK (1) DK2506716T3 (https=)
DO (2) DOP2012000151A (https=)
EC (1) ECSP12011979A (https=)
ES (1) ES2637588T3 (https=)
HK (1) HK1256947A1 (https=)
HR (1) HRP20171175T1 (https=)
HU (2) HUE033099T2 (https=)
IL (4) IL220054A (https=)
LT (2) LT2506716T (https=)
LU (1) LUC00149I2 (https=)
ME (1) ME02800B (https=)
MX (1) MX346959B (https=)
MY (1) MY167076A (https=)
NL (1) NL301035I2 (https=)
NO (1) NO2020006I1 (https=)
NZ (1) NZ600161A (https=)
PE (1) PE20121336A1 (https=)
PH (2) PH12012501076B1 (https=)
PL (1) PL2506716T3 (https=)
PT (1) PT2506716T (https=)
RS (1) RS56317B1 (https=)
RU (2) RU2711869C3 (https=)
SG (2) SG10201407976UA (https=)
SI (1) SI2506716T1 (https=)
TW (3) TWI600656B (https=)
UY (1) UY33071A (https=)
WO (1) WO2011068881A1 (https=)
ZA (1) ZA201203999B (https=)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592231A (zh) * 2008-06-10 2015-05-06 Abbvie公司 新的三环化合物
CA2758359A1 (en) * 2009-04-14 2010-10-21 Astellas Pharma Inc. Fused pyrrolopyridine derivative
RU2711869C3 (ru) * 2009-12-01 2022-02-02 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
PH12012501000A1 (en) * 2009-12-01 2013-02-11 Abbvie Inc Novel tricyclic compounds
RU2012132278A (ru) 2010-01-12 2014-02-20 Ф. Хоффманн-Ля Рош Аг Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
CN103547580B (zh) * 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
AU2012244549B2 (en) 2011-04-21 2017-04-20 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
AU2012295802B2 (en) 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
WO2013043826A1 (en) 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
CN102516146B (zh) * 2011-11-24 2013-10-02 爱斯特(成都)生物制药有限公司 5位为氮的四元氮杂螺环衍生物及其制备方法和用途
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
JP6248948B2 (ja) * 2013-02-08 2017-12-20 日産化学工業株式会社 3環性ピロロピリジン化合物及びjak阻害剤
GEP201606600B (en) 2013-02-22 2017-01-10 Pfizer Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
CA3012383C (en) 2013-02-28 2021-03-02 Teewinot Technologies Limited Biosynthesis of cannabinoids
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
AU2014339897A1 (en) * 2013-10-24 2016-04-21 Abbvie Inc. JAK1 selective inhibitor and uses thereof
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN107001354B (zh) * 2014-04-11 2021-06-22 台北医学大学 组蛋白去乙酰酶抑制剂
BR112016023299A8 (pt) 2014-05-14 2021-06-29 Nissan Chemical Ind Ltd composto tricíclico e inibidor de jak, agente preventivo, terapêutico ou de melhoria para doenças contra as quais inibição de jak é eficaz e para artrite reumatoide, medicamento e utilização desses compostos
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
CN109593651A (zh) 2014-08-25 2019-04-09 蒂威诺特科技有限公司 用于大麻素化合物的同时生产的设备和方法
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12570664B2 (en) * 2015-10-16 2026-03-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) * 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
HK1254892A1 (zh) 2016-01-14 2019-08-02 韩德株式会社 拮抗a3腺苷受体的化合物、其制备方法、及其医学用途
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ.ベー. Jakファミリーのキナーゼの低分子阻害物質
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AU2018230500B2 (en) 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN109535164B (zh) * 2017-09-21 2022-01-18 上海华汇拓医药科技有限公司 Jak激酶抑制剂及其制备方法和在医药领域的应用
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
CN110872250B (zh) * 2018-08-31 2023-01-10 苏州鹏旭医药科技有限公司 两种化合物及其制备方法和在合成乌西替尼中的用途
US11926633B2 (en) 2018-08-31 2024-03-12 Suzhou Pengxu Pharmatech Co., Ltd Synthesis methods for upadacitinib and intermediate thereof
CN113396150B (zh) 2018-11-01 2024-03-12 凌科药业(杭州)有限公司 三环janus激酶1抑制剂及其组合物和方法
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN111217819B (zh) * 2018-11-27 2021-05-14 杭州科巢生物科技有限公司 乌帕替尼的合成方法
WO2020115212A1 (en) 2018-12-05 2020-06-11 Lek Pharmaceuticals D.D. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
WO2020115213A1 (en) 2018-12-07 2020-06-11 Lek Pharmaceuticals D.D. Solvate of a selective jak1 inhibitor
CN109761885B (zh) * 2019-02-21 2020-06-26 北京悦康科创医药科技股份有限公司 一种阿加曲班异构体杂质的拆分方法
US20210380596A1 (en) * 2019-03-01 2021-12-09 Crystal Pharmaceutical (Suzhou) Co., Ltd. Upadacitinib crystal form and preparation method therefor and use thereof
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
EP3939979A4 (en) 2019-03-14 2022-04-06 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
WO2020202183A1 (en) 2019-03-29 2020-10-08 Mylan Laboratories Limited The process for the preparation of upadacitinib and its intermediates
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
EP4006028B1 (en) * 2019-07-26 2025-07-02 Zhuhai Yufan Biotechnologies Co., Ltd Irak4 kinase inhibitor and preparation method therefor
CN110938048B (zh) * 2019-12-02 2023-03-28 四川大学 路易酸催化的插入反应高效合成二氢呋喃衍生物
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Fgfr阻害剤の誘導体
EP4077276A1 (en) 2019-12-19 2022-10-26 Curia Spain S.A.U. Process and intermediates for the preparation of upadacitinib
CN111007184B (zh) * 2019-12-30 2023-05-16 天津天士力圣特制药有限公司 一种4-甲基哌嗪-1-甲酰氯盐酸盐含量的检测方法
WO2021176473A1 (en) 2020-03-05 2021-09-10 Mylan Laboratories Limited A process for the preparation of upadacitinib and its intermediates
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
US20210371389A1 (en) * 2020-04-24 2021-12-02 Kansas Soybean Commission One-step synthesis of soybean polyols
WO2021244323A1 (zh) * 2020-06-05 2021-12-09 苏州科睿思制药有限公司 一种乌帕替尼的晶型及其制备方法和用途
KR20230038229A (ko) 2020-07-08 2023-03-17 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도
WO2022044037A1 (en) 2020-08-24 2022-03-03 Mylan Laboratories Limited An improved process for the preparation of upadacitinib intermediate
CN117015543A (zh) * 2020-09-14 2023-11-07 高德美控股有限公司 新型jak抑制剂化合物、其合成方法及其用途
BR112023004550A2 (pt) * 2020-10-08 2023-05-02 Unichem Lab Ltd Compostos tricíclicos substituídos
CN112578034B (zh) * 2020-11-04 2022-02-11 广东众生睿创生物科技有限公司 一种手性胺小分子及其盐的质量控制方法
CN114790208B (zh) * 2021-01-26 2024-06-07 珠海宇繁生物科技有限责任公司 一种irak4激酶抑制剂及其制备方法
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
KR20230167057A (ko) * 2021-04-07 2023-12-07 애브비 인코포레이티드 유파다시티닙의 공결정
CN113200967B (zh) * 2021-05-07 2022-05-24 中国人民解放军陆军军医大学 吲哚苯醌类化合物、其制备方法及其应用
AU2022271927B2 (en) * 2021-05-13 2025-07-10 Innovstone Therapeutics Limited Compound having anti-tumor activity and use thereof
CN113603693B (zh) * 2021-07-13 2022-08-26 陕西丽彩药业有限公司 一种2-溴-5-对甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪的制备方法
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
CN116836171B (zh) * 2023-06-30 2024-06-04 凌科药业(杭州)有限公司 一种磺酰胺类化合物及其应用
WO2025102268A1 (en) * 2023-11-15 2025-05-22 Lynk Pharmaceuticals Co. Ltd. Solid state forms, pharmaceutical compositions, preparation methods and use thereof
CN117285537B (zh) * 2023-11-27 2024-02-06 中节能万润股份有限公司 一种乌帕替尼的制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB716327A (en) 1951-09-05 1954-10-06 Ici Ltd New heterocyclic compounds
US3663559A (en) 1969-12-03 1972-05-16 Union Carbide Corp Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4053474A (en) 1976-04-21 1977-10-11 E. R. Squibb & Sons, Inc. Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE69033614T2 (de) 1989-10-20 2001-04-19 Kyowa Hakko Kogyo K.K., Tokio/Tokyo Kondensierte Purinderivate
KR927003044A (ko) 1990-01-11 1992-12-17 크리스토퍼 케이. 미라벨리 Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
DK0559751T3 (da) 1990-11-26 1997-10-06 Robert R Recker Behandling af osteoporosis under anvendelse af væksthormonfrigivende faktor (GRF) i kombination med parathyreoideahormon (PTH)
EP1857553A1 (en) 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
KR100207360B1 (ko) 1991-06-14 1999-07-15 돈 더블유. 슈미츠 이미다조[1,5,-a]퀸옥살린
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5939419A (en) 1993-02-26 1999-08-17 Schering-Plough Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5733905A (en) 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5736540A (en) 1993-07-29 1998-04-07 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
RU2158127C2 (ru) 1994-12-23 2000-10-27 Варнер-Ламберт Компани Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5763137A (en) 1995-08-04 1998-06-09 Agfa-Gevaert, N.V. Method for making a lithographic printing plate
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2322311C (en) * 1998-03-04 2009-10-13 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
JP4100865B2 (ja) * 1999-12-13 2008-06-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 三環式縮合異項環化合物、その製造法およびその医薬
PY0119496A (es) 2000-08-07 2003-11-03 Neurogen Corp Compuestos heterociclicos como ligandos de receptores gabaa
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
US20050176796A1 (en) 2002-02-19 2005-08-11 D'alessio Roberto Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
DE60333762D1 (de) * 2002-08-23 2010-09-23 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200524864A (en) * 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
PE20060526A1 (es) * 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
DE502005008916D1 (de) 2004-07-23 2010-03-11 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
WO2006058120A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
WO2006074984A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
EP1846408B1 (en) * 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
US20060183758A1 (en) 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
EP1863813A2 (en) * 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
US7737279B2 (en) * 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
CN101223168A (zh) * 2005-07-14 2008-07-16 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US7589101B2 (en) * 2005-08-16 2009-09-15 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2006292119A1 (en) 2005-09-23 2007-03-29 3M Innovative Properties Company Method for 1H-imidazo[4,5-c]pyridines and analogs thereof
JP5052518B2 (ja) * 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
JP5249772B2 (ja) 2005-11-22 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション キナーゼの阻害剤として有用な三環式化合物
ES2545907T3 (es) 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
EP2468748B1 (en) * 2006-02-15 2016-05-25 AbbVie Inc. Pyrazoloquinolones are potent parp inhibitors
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
EP2068869A4 (en) * 2006-10-06 2011-05-25 Abbott Lab NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE
AR064879A1 (es) * 2007-01-12 2009-04-29 Astellas Pharma Inc Compuesto de piridina condensado
CA2676665A1 (en) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Modulators of mitotic kinases
WO2008112695A2 (en) 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
CA2682304A1 (en) 2007-04-04 2008-10-16 F. Hoffmann-La Roche Ag Microbial reduction of an acetoxyketone
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CA2924436A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
PE20091485A1 (es) * 2008-02-06 2009-10-26 Novartis Ag DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS
CN101945877B (zh) 2008-02-25 2013-07-03 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
JP5368485B2 (ja) 2008-02-25 2013-12-18 エフ.ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
CA2712507A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
CN104592231A (zh) * 2008-06-10 2015-05-06 Abbvie公司 新的三环化合物
US20110201599A1 (en) * 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
CA2758359A1 (en) * 2009-04-14 2010-10-21 Astellas Pharma Inc. Fused pyrrolopyridine derivative
US8361962B2 (en) * 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
PH12012501000A1 (en) 2009-12-01 2013-02-11 Abbvie Inc Novel tricyclic compounds
RU2711869C3 (ru) 2009-12-01 2022-02-02 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012149280A2 (en) 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
WO2013043826A1 (en) 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
AU2014339897A1 (en) 2013-10-24 2016-04-21 Abbvie Inc. JAK1 selective inhibitor and uses thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Similar Documents

Publication Publication Date Title
JP2013512280A5 (https=)
RU2015144809A (ru) Новые трициклические соединения
RU2010153582A (ru) Новые трициклические соединения
KR101585848B1 (ko) 관절염의 치료 방법
CA2820618C (en) Use of sulfonylbenzamide compounds in the treatment of systemic lupus erythematosus, lupus nephritis, or sjogren's syndrome
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2016539927A (ja) Jak1選択的阻害剤とその使用
WO2012127506A4 (en) Substituted fused tricyclic compounds, compositions and medicinal applications thereof
JP2013515074A5 (https=)
JP2010540527A (ja) ケモカイン受容体拮抗薬としてのオクタヒドロペンタレン化合物
US20190105314A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20200054622A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
JP2024516430A5 (https=)
TWI797366B (zh) 吡咯并[1,2-b]嗒衍生物
US20070049608A1 (en) Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use
EP3856195A1 (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK1243076A1 (zh) 作為布羅莫結構域抑制劑的取代的吡咯並吡啶
HK1224937B (en) Methods of treatment using selective bcl-2 inhibitors